PRIMARY PERITONEAL CARCINOMA

This early-phase study tests a new drug called AI-061, which combines two immunotherapy agents (anti-PD-1 and anti-CTLA-4) into one treatment. The goal is to find the safest dose and see if it can shrink tumors in people with advanced cancers like melanoma, lung, and ovarian canc…

This early-phase trial tests a new drug called IMGN151 in adults with certain gynaecological cancers that have come back. The study aims to find a safe dose and check for side effects. About 256 participants with recurrent endometrial, ovarian, fallopian tube, primary peritoneal,…

This study tests a combination of two drugs, ONC-392 and pembrolizumab, in 58 women with ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the combo can shrink tumors and control the disease. Participants must have a specific type of…

This study tests a new oral drug called sovilnesib in people with advanced high-grade serous ovarian cancer that no longer responds to platinum chemotherapy. The main goal is to find the best dose that is safe and effective. About 120 adults will take the pill daily, and research…

This study tests whether the immunotherapy drug nivolumab, alone or combined with ipilimumab, can shrink tumors in people with advanced clear cell carcinoma of the ovary, fallopian tube, peritoneum, or other organs. About 46 participants with recurrent or metastatic disease will …

This phase 2 study tested whether combining an experimental vaccine (DPX-Survivac) with an immunotherapy drug (pembrolizumab) and low-dose chemotherapy can shrink tumors in people with advanced ovarian, fallopian tube, or peritoneal cancer. The vaccine trains the immune system to…

This study tested a combination of two drugs, olaparib and cediranib, in 70 people with ovarian, peritoneal, or fallopian tube cancer that had returned after initial treatment. The goal was to see if the drugs could slow or stop tumor growth by blocking enzymes cancer cells need …

This pilot study tested whether a prehabilitation program is practical and helpful for women with advanced ovarian cancer who receive chemotherapy before surgery. The program aims to improve patients' strength and well-being before their operation. 22 women participated, and the …

This study follows 100 women with breast or gynecological cancer to see if what they eat in the month before starting chemotherapy is linked to levels of a protein called hepcidin. Researchers will also check if hepcidin levels relate to how much of the planned chemo dose patient…

This study collects tissue and blood samples, along with medical information, from 1,600 people with various advanced cancers. The goal is to track how cancer changes over time and during treatment. Researchers hope this will help them understand why some cancers resist therapy a…